D
Werewolf Therapeutics, Inc.
HOWL
$0.7103
-$0.0823-10.38%
D
Sell
1/6/2025Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
E
Sell
12/20/2024Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 12/20/2024 due to a decline in the volatility index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 12/20/2024 due to a decline in the volatility index.
D
Sell
12/2/2024Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 12/2/2024 due to an increase in the total return index and volatility index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 12/2/2024 due to an increase in the total return index and volatility index.
E
Sell
11/15/2024Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 11/15/2024 due to a noticeable decline in the total return index, growth index and volatility index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 11/15/2024 due to a noticeable decline in the total return index, growth index and volatility index.
D
Sell
1/31/2024Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 1/31/2024 due to an increase in the total return index, volatility index and valuation index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 1/31/2024 due to an increase in the total return index, volatility index and valuation index.
E
Sell
1/16/2024Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 1/16/2024 due to a decline in the volatility index and valuation index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 1/16/2024 due to a decline in the volatility index and valuation index.
D
Sell
12/27/2023Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 12/27/2023 due to an increase in the volatility index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 12/27/2023 due to an increase in the volatility index.
E
Sell
12/7/2023Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 12/7/2023 due to a decline in the volatility index and total return index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 12/7/2023 due to a decline in the volatility index and total return index.
D
Sell
11/20/2023Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 11/20/2023 due to an increase in the volatility index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 11/20/2023 due to an increase in the volatility index.
E
Sell
11/8/2023Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 11/8/2023 due to a decline in the volatility index, total return index and valuation index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 11/8/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
10/23/2023Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 10/23/2023 due to an increase in the volatility index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 10/23/2023 due to an increase in the volatility index.
E
Sell
10/4/2023Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 10/4/2023 due to a decline in the volatility index and total return index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 10/4/2023 due to a decline in the volatility index and total return index.
D
Sell
9/18/2023Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 9/18/2023 due to an increase in the volatility index, total return index and valuation index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 9/18/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
8/29/2023Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index.
D
Sell
8/14/2023Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 7.1 to 9.62.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 7.1 to 9.62.
E
Sell
8/8/2023Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 8/8/2023 due to a decline in the growth index and volatility index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 8/8/2023 due to a decline in the growth index and volatility index.
D
Sell
7/21/2023Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 7/21/2023 due to an increase in the growth index, total return index and solvency index. The quick ratio increased from 5.68 to 7.1, operating cash flow increased 16.61% from -$11.87M to -$9.9M, and earnings per share increased from -$0.3882 to -$0.3445.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 7/21/2023 due to an increase in the growth index, total return index and solvency index. The quick ratio increased from 5.68 to 7.1, operating cash flow increased 16.61% from -$11.87M to -$9.9M, and earnings per share increased from -$0.3882 to -$0.3445.
E
Sell
3/14/2023Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D on 03/14/2023.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D from E+ on 02/09/2023.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and valuation index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and valuation index.
D
Sell
11/14/2022Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D from D- on 11/14/2022 due to a noticeable increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.5304 to -$0.4013, total revenue increased 19.82% from $4.15M to $4.97M, and EBIT increased 16.25% from -$14.97M to -$12.54M.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D from D- on 11/14/2022 due to a noticeable increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.5304 to -$0.4013, total revenue increased 19.82% from $4.15M to $4.97M, and EBIT increased 16.25% from -$14.97M to -$12.54M.
D
Sell
11/10/2022Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to D- from D on 11/10/2022 due to a decline in the volatility index and total return index.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to D- from D on 11/10/2022 due to a decline in the volatility index and total return index.
D
Sell
9/6/2022Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D from D- on 9/6/2022 due to an increase in the total return index and volatility index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D from D- on 9/6/2022 due to an increase in the total return index and volatility index.
D
Sell
5/12/2022Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 5/12/2022 due to a substantial increase in the growth index and solvency index. Earnings per share increased from -$0.6553 to -$0.5601, and EBIT increased 14.08% from -$17.88M to -$15.37M.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E+ on 5/12/2022 due to a substantial increase in the growth index and solvency index. Earnings per share increased from -$0.6553 to -$0.5601, and EBIT increased 14.08% from -$17.88M to -$15.37M.
E
Sell
3/25/2022Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 3/25/2022 due to a major decline in the efficiency index, growth index and total return index. Net income declined 29.88% from -$13.76M to -$17.87M, EBIT declined 29.64% from -$13.8M to -$17.88M, and earnings per share declined from -$0.506 to -$0.6553.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E+ from D- on 3/25/2022 due to a major decline in the efficiency index, growth index and total return index. Net income declined 29.88% from -$13.76M to -$17.87M, EBIT declined 29.64% from -$13.8M to -$17.88M, and earnings per share declined from -$0.506 to -$0.6553.
D
Sell
1/3/2022Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E on 01/03/2022.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to D- from E on 01/03/2022.
E
Sell
12/27/2021Downgrade
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E from E+ on 12/27/2021 due to a noticeable decline in the total return index, volatility index and efficiency index. Net income declined 25.98% from -$10.92M to -$13.76M, and total capital declined 6.76% from $183.77M to $171.34M.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E from E+ on 12/27/2021 due to a noticeable decline in the total return index, volatility index and efficiency index. Net income declined 25.98% from -$10.92M to -$13.76M, and total capital declined 6.76% from $183.77M to $171.34M.
E
Sell
10/1/2021Upgraded
Werewolf Therapeutics, Inc. (HOWL) was upgraded to E+ from E on 10/1/2021 due to an increase in the total return index.
Werewolf Therapeutics, Inc. (HOWL) was upgraded to E+ from E on 10/1/2021 due to an increase in the total return index.
E
Sell
8/13/2021None
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E from U on 08/13/2021.
Werewolf Therapeutics, Inc. (HOWL) was downgraded to E from U on 08/13/2021.
NASDAQ
04/04/2025 12:52PM Eastern
Quotes delayed
